Vancenase

Vancenase

 [van´sĕ-nāz″]
trademark for preparations of beclomethasone dipropionate, a glucocorticoid used to treat allergic rhinitis and other allergic and inflammatory nasal conditions.
References in periodicals archive ?
fluticasone), Nasacort (triamcinolone), Nasalide (flunisolide), Nasonex (mometasone), Rhinocort (budesonide), Vancenase DS or Vancenase Pockethaler (beclomethasone) Inhaled.
But prescription nasal sprays, or topical steroids such as Vancenase, Flonase, Rhinocort or Nasacort, work very well for allergy sufferers without fear of dependency.
Sold under the names Nasalide, Beconase and Vancenase, these drugs may totally eliminate sneezing, itching and nasal discharge and, when used carefully and according to directions, may provide welcome relief year after year.
Table 43: UK Market for Inhaled Drug Delivery Systems (2004): Percentage Share Breakdown of Sales by Major Brands- Serevent, Ventolin, Pulmicort, Flovent, Beclovent, Atrovent, Flonase, Vancenase Pocket, Vancenase, and Other (includes corresponding Graph/Chart) III-35 Areas of Growth III-35 Progress in Drug Delivery III-36 Asthma Incidence among Children III-36 Product Launches/Developments III-36 Strategic Corporate Developments III-37 Select Players III-41 B.
Well-established medications include Nasalcrom, Vancenase and other steroidal nasal sprays.
The sales decline was due to lower sales of VANCENASE and the VANCERIL(R) (beclomethasone dipropionate) line of orally inhaled steroids for asthma; lower sales of K-DUR, and lower sales of the INTRON A franchise.
Sales growth by therapeutic category was led by: in allergy/respiratory, CLARITIN, NASONEX, VANCENASE and VANCERIL; in anti- infective/anticancer, INTRON A; in cardiovasculars, IMDUR and K-DUR; and in dermatologicals, LOTRISONE and ELOCON.
were led by the CLARITIN line, VANCENASE, INTRON A and LOSEC(R)
Sales growth was led by the CLARITIN line, IMDUR, INTRON A, K-DUR, VANCERIL, VANCENASE, LOTRISONE and ELOCON(R) (mometasone furoate), a medium-potency topical steroid.
Sales growth was led by the CLARITIN line, INTRON A, IMDUR, VANCENASE, K-DUR, VANCERIL, LOTRISONE and ELOCON.
Sales growth was led by the allergy/asthma products CLARITIN, VANCENASE and VANCERIL; by the cardiovascular products IMDUR and K-DUR; and by CEDAX and INTRON A in the anti-infective/anticancer products category.